Tracking the source of the hepatitis B virus-specific CD8 T cells during lamivudine treatment

Journal of Infectious Diseases

Volumn 187, Issue 4, 2003, Pages 679-682

  Malacarne, Fabio ^a   Webster, George J M ^a   Reignat, Stephanie ^a   Gotto, Jim ^a   Behboudi, Shahriar ^a   Burroughs, Andrew K ^a   Dusheiko, Geoffrey M ^a   Williams, Roger ^a   Bertoletti, Antonio ^a,b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD8 ANTIGEN; LAMIVUDINE;

ARTICLE; BLOOD; CASE REPORT; CONTROLLED STUDY; CYTOKINE PRODUCTION; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOSTIMULATION; LIVER; LIVER TRANSPLANTATION; LYMPH NODE; PRIORITY JOURNAL; STEM CELL; T LYMPHOCYTE;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; FLOW CYTOMETRY; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; LYMPH NODES; SPECIES SPECIFICITY;

EID: 0037443117     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/368369     Document Type: Article

References (14)

1. Ganem D. Towards a rational treatment for hepatitis B. J Clin Invest 1998; 102:867-8.
2. Couillin I, Pol S, Mancini M, et al. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J Infect Dis 1999; 180:15-26.
3. Michel ML, Loirat D. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology 2001; 44:78-87.
4. Pol S, Nalpas B, Driss F, et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34:917-21.
5. Lanzavecchia A, Sallusto F. Dynamic of T lymphocyte responses: intermediates, effectors and memory cells. Science 2000; 290:92-7.
6. Boni C, Penna A, Ogg G, et al. Lamivudine treatment can overcome cytotoxic T cell hyporesponsiveness in chronic hepatitis B: new perspective for immune therapy. Hepatology 2001; 33:963-71.
7. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest 1998; 102:968-75.
8. + T cells associated with the control of infection. Gastroenterology 1999; 117:1386-96.
9. Bertoletti A, D'Elios MM, Boni C, et al. Different cytokine profiles of intrahepatic T cells in chronic hepatitis B and hepatitis C virus infections. Gastroenterology, 1997; 112:193-9.
10. + cells in viral control and liver damage during persistent hepatitis B virus (HBV) infection. J Exp Med 2000; 191:1269-80.
11. Barnaba V, Franco A, Alberti A, Balsano C, Benvenuto R, Balsano F. Recognition of hepatitis B envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J Immunol 1989; 143:2650-5.
12. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65-91.
13. Fukuda R, Ishimura N, Nguyen TX, et al. The expression of IL-2, IL-4 and interferon-gamma (IFN-gamma) mRNA using liver biopsies at different phases of acute exacerbation of chronic hepatitis B. Clin Exp Immunol 1995; 100:446-51.
14. Maruyama T, McLachlan A, Iino S, Koike K, Kurokawa K, Milich D. The serology of chronic hepatitis B infection revisited. J Clin Invest 1993; 91:2586-95.